



SmartPA Criteria Proposal

Drug/Drug Class:	Corlanor Clinical Edit
First Implementation Date:	December 3, 2018
Revised Date:	April 27, 2023
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of Corlanor® (ivabradine)

Why Issue Selected: Corlanor® (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker used in stable symptomatic heart failure. It is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. In 2019, Corlanor also received an indication for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients aged 6 months and older. Corlanor should not be used as a substitute for beta blockers unless the patient is on maximally tolerated doses of beta blockers or if beta blockers are contraindicated. Currently there is much more evidence for beta blockers in heart failure than for Corlanor. Beta blockers have been shown to decrease death due to heart failure, cardiovascular death, and all-cause mortality while Corlanor has only been shown to decrease death due to heart failure. Given the well-proven mortality benefits of beta-blocker therapy, it is important to initiate and up titrate these agents to target doses, as tolerated, before assessing the resting heart rate for consideration of initiation of Corlanor therapy.

Program-Specific Information:	Date Range FFS 10-01-2021 to 9-30-2022			
	Drug	Claims	Spend	Average Spend per Claim
	CORLANOR 5 MG TABLET	746	\$324,652.58	\$435.19
	CORLANOR 7.5 MG TABLET	207	\$96,021.14	\$463.87
	CORLANOR 5 MG/5 ML SOLN	0	-	-

Type of Criteria: ☐ Increased risk of ADE
☒ Appropriate Indications

☐ Preferred Drug List
☒ Clinical Edit

Data Sources: ☐ Only Administrative Databases

☒ Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Corlanor® (ivabradine)

SmartPA Clinical Proposal Form

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

- Age range: All appropriate MO HealthNet participants aged 6 months and older

Approval Criteria

- Documented history of Corlanor therapy in the past 60 days **OR**
- Prescribed by or in consultation with a cardiologist or other specialist for the treated disease state **AND**
- Participant aged ≥ 6 months and < 18 years:
 - Documented diagnosis of heart failure due to dilated cardiomyopathy **AND**
 - Participant is in sinus rhythm **AND**
 - Participant has an appropriate heart rate for therapy based on age:
 - Aged 6-12 months: ≥ 105 beats per minute
 - Aged 1-3 years: ≥ 95 beats per minute
 - Aged 3-5 years: ≥ 75 beats per minute
 - Aged 5 years and older: ≥ 70 beats per minute **OR**
- Participant aged ≥ 18 years:
 - Documented therapy with a beta blocker for 60 out of the past 90 days **OR**
 - Documented contraindications to beta blocker therapy **AND**
 - Participant has a left ventricular ejection fraction of 35% or less **AND**
 - Participant is in sinus rhythm **AND**
 - Participant has a resting heart rate of at least 70 beats per minute **OR**
- Approval based on clinical consultant review

Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Documented history of severe hepatic impairment

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

X

Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)
Rule Type: CE

Default Approval Period

3 months

References

- CORLANOR® (ivabradine) [package insert]. Thousand Oaks, CA: Amgen Inc.; August 2021.
- IPD Analytics. Cardiovascular: Heart Failure. Accessed October 18, 2022.
- Heidenreich PA, Bozkurt B, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895–e1032.
- Maddox TM, Januzzi JL Jr, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With

SmartPA Clinical Proposal Form

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries. Other company trademarks are also acknowledged.

Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772-810. doi:10.1016/j.jacc.2020.11.022